The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Surveillance of Complex Renal Cysts - The SOCRATIC Study
Official Title: Surveillance of Complex Renal Cysts - The SOCRATIC Study
Study ID: NCT04558593
Brief Summary: One third of individuals aged \>60 years will be diagnosed with at least one renal cyst following abdominal imaging. These cystic lesions are categorized according to the Bosniak classification which categorizes cysts according to their degree of complexity and risk of malignancy. Growing evidence suggests that a significant proportion of Bosniak III and IV cysts are benign and that the malignant ones present low metastatic potential. Since renal surgery carries substantial morbidity (20%) and potential mortality (0.5%), active surveillance has gained attention as a potential tradeoff to surgery to overcome overtreatment. Therefore, prospective studies of long-term follow-up are needed to confirm the oncologic safety of this strategy for patients with Bosniak III/IV cysts. This is an multicenter prospective observational longitudinal study. The main objective is to compare the 5-year follow-up cancer-specific survival between the active surveillance and the surgical groups.
Detailed Description: Background: One in three patients over 60 years old will be diagnosed with a renal cyst following abdominal imaging. Traditionally, experts have recommended that complex cystic lesions (also known as Bosniak III - IV cysts) should be surgically removed, but recent evidences suggest that many are benign or have low metastatic potential. Thus, active surveillance which involves close follow-up of a patient's condition, was proposed as a tradeoff option to surgery. Design: Multicenter observational longitudinal prospective cohort study Objectives: The goal of this multicenter project is to conduct a prospective study with a 5-year follow-up to confirm the oncologic outcomes of active surveillance in the management of complex cysts. The main objectives are: 1) to compare the 5-year cancer specific survival between cysts managed by surgery and active surveillance; 2) to evaluate disease progression; 3) to evaluate patient's well-being according to each management strategy; and 4) to compare the 5-year healthcare cost of both management approaches. Study population: Patients incidentally diagnosed with a Bosniak III and/or IV cysts, who are deemed to have at least 5 years of life, and who opted to be managed by either surgery or active surveillance. (N=330) Follow-up: Patients will DECIDE if they want to have a surgery or to be followed by active surveillance. All patients will be followed as per standard of care with either semi-annual and annual visits. Research visits will serve to assess vital status and quality of life scores (through validated questionnaires). Patients on active surveillance will also be assessed for cyst progression and might be offered invasive or systemic therapy if progression is observed.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Prostate Cancer Center, Calgary, Alberta, Canada
Northern Alberta Urology Center, Edmonton, Alberta, Canada
Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
St-Joseph's Hospital, Hamilton, Ontario, Canada
The Ottawa Hospital, Ottawa, Ontario, Canada
Thunder Bay Health Sciences Center, Thunder Bay, Ontario, Canada
Princess Margaret Hospital, Toronto, Ontario, Canada
Woodstock hospital, Woodstock, Ontario, Canada
Centre intégré de santé et de services sociaux de Chaudière-Appalaches - Hôtel-Dieu de Lévis, Lévis, Quebec, Canada
CHUM, Montreal, Quebec, Canada
Hôpital Maisonneuve-Rosemont (CISSS-EIMtl), Montreal, Quebec, Canada
McGill University Health Centre, Montreal, Quebec, Canada
CHU de Québec - Université Laval, Québec, Quebec, Canada
Centre de recherche du Centre hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
Vancouver Prostate Centre, Vancouver, , Canada
CHU Bordeaux (URO-CCR), Bordeaux, , France
Name: Patrick O Richard, MD,MSc,FRCSC
Affiliation: Université de Sherbrooke
Role: PRINCIPAL_INVESTIGATOR